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Schizophrenia is associated with disruptions in
N-methyl-D-aspartate glutamate receptor subtype
(NMDAR)-mediated excitatory synaptic signaling.
The metabotropic glutamate receptor subtype 5
(mGlu5) is a closely associated signaling partner
with NMDARs and regulates NMDAR function in
forebrain regions implicated in the pathology of
schizophrenia. Efficacy of mGlu5 positive allosteric
modulators (PAMs) in animal models of psychosis
and cognition was previously attributed to potentia-
tion of NMDAR function. To directly test this hypoth-
esis, we identified VU0409551 as a novel mGlu5
PAM that exhibits distinct stimulus bias and selec-
tively potentiates mGlu5 coupling to Gaq-mediated
signaling but not mGlu5 modulation of NMDAR cur-
rents or NMDAR-dependent synaptic plasticity in
the rat hippocampus. Interestingly, VU0409551
produced robust antipsychotic-like and cognition-
enhancing activity in animal models. These data pro-
vide surprising new mechanistic insights into the
actions of mGlu5 PAMs and suggest that modulation
of NMDAR currents is not critical for in vivo efficacy.
INTRODUCTION
Multiple clinical and genetic studies have led to the hypothesis
that hypofunction of the N-methyl-D-aspartate subtype of gluta-
mate receptor (NMDAR) plays an important role in the patho-physiology of schizophrenia and that administration of agents
that enhance NMDAR function can provide symptomatic
improvement in schizophrenic patients (Coyle et al., 2012; Field
et al., 2011; Timms et al., 2013). Based on these findings, multi-
ple efforts have focused on developing approaches to enhance
NMDAR signaling as a potential novel treatment strategy for
schizophrenia. Metabotropic glutamate receptor subtype 5
(mGlu5) is a closely associated signaling partner with theNMDAR
and activation of mGlu5 potentiates NMDAR responses and
NMDAR-mediated synaptic plasticity in forebrain regions impli-
cated in the pathology of schizophrenia (Ayala et al., 2009; Col-
lingridge et al., 1983; Doherty et al., 1997; Homayoun et al., 2004;
Mannaioni et al., 2001; Marino and Conn, 2002). Consistent with
this, deletion or blockade of mGlu5 exacerbates psychotomi-
metic-like and cognition-disrupting effects of NMDAR antago-
nists (Brody et al., 2004; Campbell et al., 2004; Henry et al.,
2002; Kinney et al., 2003), and highly selective mGlu5 positive
allosteric modulators (PAMs) potentiate mGlu5-mediated regula-
tion of NMDAR currents and have cognition-enhancing and anti-
psychotic-like effects in preclinical models (Ayala et al., 2009;
Darrah et al., 2008; Gastambide et al., 2013; Gregory et al.,
2013a; Kinney et al., 2005; Liu et al., 2008; Noetzel et al., 2012;
Parmentier-Batteur et al., 2014; Rodriguez et al., 2010). How-
ever, activation of mGlu5 hasmultiple actions in forebrain circuits
and the hypothesis that mGlu5-induced potentiation of NMDAR
currents is required for in vivo efficacy of mGlu5 PAMs has not
been directly tested.
The majority of actions of mGlu5 are mediated by activation of
the Gaq GTP-binding protein subunit (Niswender and Conn,
2010), whereas mGlu5-induced potentiation of NMDAR currents
in forebrain neurons is mediated by interactions of mGlu5 with
NMDARs through adaptor proteins that are independent of
signaling through Gaq (Gao et al., 2013; Hu et al., 2012; ParkNeuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc. 1029
et al., 2013; Shepherd and Huganir, 2007). We now report
discovery and characterization of a novel mGlu5 PAM,
VU0409551, that induces a robust potentiation ofmGlu5 coupling
to Gaq-mediated calcium mobilization and other signaling path-
ways but does not enhance mGlu5 modulation of NMDAR
currents in hippocampal neurons. In addition, VU0409551 poten-
tiates NMDAR-independent long-term depression (LTD) but
does not potentiate NMDAR-dependent long-term potentiation
(LTP) in the rat hippocampus. Interestingly, VU0409551produces
robust, dose-dependent efficacy in preclinical rodent models of
psychosis and cognitive function. These studies challenge the
prevailing hypothesis that the in vivo effects of mGlu5 PAMs in
models related to schizophrenia and cognitive function aremedi-
ated by potentiation of mGlu5 modulation of NMDAR currents
and provide important new insights into modulation for specific
effects of mGlu5 activation.
RESULTS
VU0409551 Is a Potent, Highly Selective Potentiator of
mGlu5
We have identified multiple mGlu receptor PAMs, including
PAMs that display striking stimulus bias and selectively poten-
tiate coupling of mGlu receptors to specific signaling pathways
(Hammond et al., 2010; Noetzel et al., 2013; Sheffler and
Conn, 2008; Zhang et al., 2005). Based on these studies, we initi-
ated an effort to optimize novel mGlu5 PAMs that potentiate
mGlu5-mediated Gaq signaling and calcium mobilization but do
not potentiate coupling of mGlu5 to modulation of NMDAR cur-
rents and possess physicochemical and pharmacokinetic prop-
erties suitable for systemic dosing, a characteristic not achieved
with previous biased mGlu5 PAMs. This culminated in the dis-
covery of VU0409551 as a potent mGlu5 PAM (Figure S1).
VU0409551 behaved as a classic mGlu5 PAM (Conn et al.,
2014) in rat mGlu5-expressing HEK293A cells and did not
possess intrinsic agonist activity (Figure 1A) but potentiated
the response to an EC20 concentration of glutamate with an
EC50 of 235 nM (Figure 1B). Increasing concentrations of
VU0409551 resulted in progressive leftward shifts in the gluta-
mate concentration-response curve with a maximum fold shift
of 11 at a 30 mM concentration of VU0409551 (Figure 1C).
VU0409551 (10 mM) is highly selective for mGlu5 and had no ef-
fect at the other mGlu receptor subtypes (Figure 1D). Addition-
ally, radioligand competition binding assays revealed that
VU0409551 (10 mM) displays weak affinity for a2A adrenergic re-
ceptors (IC50 8.9 mM) but has no activity at any of 66 other recep-
tors and ion channels (Table S1). These studies indicate that
VU0409551 is a potent and highly selective pure PAM of
mGlu5-mediated calcium mobilization.
VU0409551-Induced ERK Phosphorylation
VU0409551 also potentiated glutamate-induced phosphoryla-
tion of extracellular signal-regulated kinase 1/2 (pERK1/2) in
mGlu5-expressing cells (Figure 1E). In addition, VU0409551
increased pERK1/2 in the absence of added glutamate. This is
similar to effects of other mGlu5 PAMs, which can also display
agonist activity in this assay with greater efficacy than glutamate
(Gregory et al., 2012, 2013b). Analysis of these datawith an oper-1030 Neuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc.ational model of allosterism (Gregory et al., 2012) allowed for
quantification of VU0409551 agonist efficacy (tB: 1.04), affinity
(KB: 89 nM), and cooperativity (b: 1.43) with glutamate.
VU0409551-Induced Modulation of mGlu5 in Native
Systems
We next assessed the ability of VU0409551 to potentiate mGlu5
signaling in CNS preparations. Similar to its effects in HEK293A-
mGlu5 cells, VU0409551 had no intrinsic agonist activity in
cultured rat cortical astrocytes (Peavy et al., 2002) but potenti-
ated glutamate-induced calcium mobilization in these cells
(EC50 = 317 ± 1 nM; Figure 1F). This effect was blocked by the
mGlu5 negative allosteric modulator (NAM) MPEP (10 mM; Fig-
ure 1F). Activation of mGlu5 also plays an important role in induc-
tion of an NMDAR-independent form of long-term depression
(LTD) at the hippocampal Schaffer collateral-CA1 (SC-CA1) syn-
apse (Huber et al., 2001; Rammes et al., 2003). To assess the ef-
fect of VU0409551 on LTD induced by the group I mGlu receptor
agonist, DHPG, we recorded field excitatory postsynaptic po-
tentials (fEPSPs) from the dendritic layer of CA1 after stimulation
of the Schaffer collaterals (Figure 2). In agreement with our pre-
vious studies (Noetzel et al., 2012, 2013), DHPG (75 mM) induced
robust LTD at the hippocampal SC-CA1 synapse measured
55 min after washout of DHPG (Figure 2B; 54.9% ± 5.3% of
baseline fEPSP slope), whereas a lower concentration of
DHPG (25 mM) induced only slight depression of fEPSPs (Fig-
ure 2B; 78.9% ± 5.7% of baseline fEPSP slope). As observed
previously with other mGlu5 PAMs (Ayala et al., 2009; Noetzel
et al., 2012, 2013), VU0409551 potentiated the response to
25 mM DHPG, inducing robust LTD (Figure 2B; 43.7% ± 4.6%
baseline). Although VU0409551 alone induced a slight depres-
sion in the fEPSP slope, this effect was transient and returned
to baseline within 10 min of washout (Figure S2). Taken together,
these data suggest that VU0409551 potentiates multiple re-
sponses to mGlu5 activation in recombinant and native systems.
VU0409551 Does Not Potentiate mGlu5 Modulation of
NMDAR Currents in CA1 Pyramidal Cells
Activation of mGlu5 potentiates NMDAR currents in multiple cell
types, including hippocampal CA1 pyramidal cells (Awad et al.,
2000; Doherty et al., 1997; Fitzjohn et al., 1996; Mannaioni
et al., 2001; O’Brien et al., 2004). Consistent with previous
studies, whole-cell patch-clamp recordings from CA1 pyramidal
cells revealed that DHPG induced a concentration-dependent
increase in inward currents evoked by application of NMDA
through a patch pipette positioned adjacent to the recorded
cell (Figures 3A–3C and 3F). Application of the recently reported
mGlu5 PAM 5PAM523 (Parmentier-Batteur et al., 2014) had no
effect on NMDA-evoked currents when added alone but poten-
tiated the effect of 3 mM DHPG on NMDAR currents (Figures 3D
and 3F). Likewise, structurally distinct mGlu5 PAMs, VU0422465
(Rook et al., 2013), ADX47273 (Liu et al., 2008), and VU0092273
(Noetzel et al., 2012), resulted in a similar potentiation of DHPG-
induced modulation of NMDAR currents (Figure 3F). In contrast,
VU0409551 had no effect on NMDAR currents either alone or in
the presence of 3 mMDHPG (Figures 3E and 3F). Consistent with
these results, current-clamp studies showed VU0409551 had no
effect on NMDA-evoked responses when applied alone (Figures
Figure 1. VU0409551 Is a Potent mGlu5 PAM in HEK293A-mGlu5 Rat Cells and Native Systems
(A) Representative raw calcium traces following the addition of 30 mM VU0409551 and the subsequent additions of EC20 and EC80 concentrations of glutamate.
(B) VU0409551 potentiates an EC20 concentration of glutamate with a potency of 235 nM in mGlu5-expressing R10A rat cells.
(C) VU0409551 shifts the glutamate concentration response curve with a maximum fold shift of 11 at 30 mM.
(D) VU0409551 did not shift the agonist concentration response curve in mGlu1,2,3,4,6,7,8-expressing cells, displaying its high selectivity for mGlu5.
(E) VU0409551 potentiates glutamate-stimulated ERK1/2 phosphorylation and exhibits robust agonist activity in this assay.
(F) VU0409551 potentiates glutamate-induced calcium mobilization in rat cortical astrocytes with a potency of 317 nM and maximum glutamate response of
79.5%, which is blocked by addition of 10 mMof the mGlu5 antagonist MPEP. Data represent mean ± SEM from two to four independent experiments performed
in duplicate or triplicate.S3B–S3D) and did not potentiate 3 mM DHPG-induced depolar-
ization or increase in NMDAR response (Figures S3A–S3D). We
also assessed the effect of VU0409551 on NMDAR-mediated
fEPSPs at the SC-CA1 synapse and found that VU0409551
had no effect on the NMDAR-fEPSP slope (Figures S3F
and S3G). Finally, voltage-clamp recordings revealed that
VU0409551 (10 mM) had no effects on the EPSCNMDA/EPSCAMPA
ratio when applied alone (Figures 3G–3J) and did not have
effects on 3 mM DHPG-induced inhibition of EPSCAMPA or the
DHPG-induced slight increase in the EPSCNMDA/EPSCAMPA ratio
(Figures 3G–3J). Taken together, these results indicate thatVU0409551 represents a unique molecular probe and behaves
as an mGlu5 PAM, potentiating multiple responses to mGlu5
activation in HEK293A-mGlu5 cells, astrocytes, and hippocam-
pal slices but does not potentiate mGlu5-mediated increases in
NMDAR currents.
VU0409551 Does Not Potentiate LTP at the SC-CA1
Synapse
Previous studies reveal that mGlu5 PAMs enhance theta burst
stimulation (TBS)-induced LTP at the SC-CA1 synapse and this
effect has been postulated to be mediated by potentiation ofNeuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc. 1031
Figure 2. VU0409551 Potentiates NMDAR-Independent Synaptic Plasticity in the Hippocampus
VU0409551 potentiates DHPG-induced long-term depression (LTD).
(A) Bath application of 75 mMDHPG for 10 min (open circle, solid line) resulted in LTD of the fEPSP slope. In contrast, bath application of 25 mMDHPG for 10 min
(gray circles, solid line) resulted in a slight decrease in fEPSP slope 55min after compoundwashout. Application of 10 mMVU0409551 for 10min (dashed line), first
alone and then in combination with 25 mMDHPG (solid line) for 10min (black circles), resulted in a significant LTD in fEPSP slope (p = 0.0005, n = 6–7). Inset shows
representative fEPSP traces for each condition for baseline (black trace) and 55 min after compound washout (gray trace).
(B) Quantification of the change in fEPSP slopemeasured 55min after compound washout. Data represent mean ± SEM. **p < 0.01, ***p < 0.001 when compared
with 25 mM DHPG.mGlu5-induced modulation of NMDAR currents (Ayala et al.,
2009; Noetzel et al., 2013). To determine the effects of
VU0409551 on induction of LTP, we initiated maximal LTP using
a standard TBS protocol (saturation TBS; four trains of 10 Hz
TBS), which resulted in a 141.1% ± 8.4% increase in fEPSP
slope, compared with baseline, when measured 35 min after
stimulation (Figures 4A and 4B). In contrast, a single train of
lower-frequency bursts resulted in a slight potentiation of the
fEPSP slope (Figures 4A and 4B; 116.2% ± 3.3% of baseline)
and was used as a threshold protocol for induction of TBS
LTP. Consistent with previous reports (Ayala et al., 2009; Noetzel
et al., 2013), pretreatment of slices with the mGlu5 PAM
VU0092273 resulted in a significant potentiation of the fEPSP
slope in response to threshold TBS (Figure 4B). In contrast, treat-
ment of hippocampal slices with VU0409551 followed by
threshold TBS had no effect on fEPSP slope, compared with
threshold TBS alone (Figure 4B; 110.4% ± 4.0% of baseline).
Similar to the LTD studies, a slight decrease in the fEPSP slope
observed following application of VU0409551 resolved within
25 min of application, which is before LTP quantification (Fig-
ure S2). The ability of VU0409551 to potentiate NMDAR-
independent mGlu-LTD but not NMDAR-dependent LTP is
consistent with the lack of effect of this mGlu5 PAM on modula-
tion of NMDAR currents.
Rat Pharmacokinetics and Brain Distribution of
VU0409551
Before using this compound for in vivo studies, we evaluated
the pharmacokinetic (PK) profile and brain distribution of
VU0409551 after systemic administration. VU0409551 exhibited
a moderate clearance from plasma (CLp; 33 ml/min/kg) with a
large volume of distribution at steady-state (Vss; 9.6 l/kg) and a1032 Neuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc.moderate half-life (t1/2; 3.9 hr) following a single intravenous
(i.v.) administration in rats (2.5 mg/kg bodyweight, Figure S4).
VU0409551 biotransformation experiments in rat hepatocytes
revealedmoderate turnover throughmultiple oxidative pathways
with mono-hydroxylation of the phenyl ring (para-position)
producing the predominant metabolite, which was inactive at
mGlu5 in in vitro assays (data not shown). A single oral (per os
[p.o.]) administration (3 mg/kg) of VU0409551 revealed high
oral bioavailability (%F = 63), a maximum concentration in
plasma (Cmax,p) of 270 nM, a time to reach maximum concentra-
tion in plasma (Tmax,p) of 1.3 hr, and an area-under-the-curve
from 0-last (AUC0-last) of 2.9 mM*hr (Figure S5). The in vitro frac-
tion of unbound VU0409551 in rat plasma (fup) of 0.07 and in rat
brain (fubr) of 0.04 suggested a brain to plasma partition coeffi-
cient (Kp) at unrestricted equilibrium ([fup]/[fubr]) of 1.8 (Table
S2). Distribution of VU0409551 to brain in vivo at 1.5 hr following
a single p.o. administration (3, 10, 30, and 100 mg/kg) revealed a
brain to plasma Kp of 2.3 and corresponding unbound brain to
plasma Kp (Kp,uu) of 1.3, suggesting the compound freely perme-
ates the blood-brain barrier (BBB), and unbound concentrations
in brain and plasma reach unrestricted equilibrium (Table S2).
Thus, VU0409551 exhibits excellent PK and brain exposure for
use in in vivo studies.
VU0409551 Induces Wake-Promoting Effects in Rats
Previous studies reveal that mGlu5 PAMs increase wakefulness
in rodents (Gilmour et al., 2013; Parmentier-Batteur et al.,
2012) and this provides an excellent measure of their in vivo
CNS activity. Acute oral administration of VU0409551 exerts
clear central activity immediately following administration, as ex-
pressed by a dose-dependent decrease in sleep. Specifically,
VU0409551 dose-dependently decreased the total time spent
Figure 3. Differential Effects of mGlu5 PAMs on Potentiation of NMDAR Currents in CA1 Pyramidal Cells of the Hippocampus
(A–C) DHPG induces a concentration-dependent increase in NMDAR currents. Top: representative traces of NMDA-evoked currents in hippocampal CA1
pyramidal cells. Bottom: time courses of normalized NMDAR current amplitude before, during, and after application of DHPG at different concentrations.
(D and E) Top: representative traces of NMDA-evoked currents. Bottom: time courses of normalized NMDAR current amplitude in control, during applications of
mGlu5 PAM alone and a combination of mGlu5 PAM and DHPG (3 mM), and after washout of the compounds. (D) The mGlu5 PAM 5PAM523 (20 mM) potentiates
the effect of DHPG on NMDAR currents. (E) VU0409551 (10 mM), a highly selective mGlu5 PAM, does not significantly potentiate NMDAR currents.
(F) Summary of DHPG and mGlu5 PAMs (p < 0.05, n = 5–8) alone and in the presence of 3 mM DHPG on NMDAR currents.
(G–J) VU0409551 does not have a significant effect on the EPSCNMDA/EPSCAMPA ratio at SC-CA1 synapses. (G and H) Representative traces of EPSCsAMPA and
EPSCs NMDA at holding potentials of –60 mV and +40 mV in controls, during application of 3 mMDHPG, 10 mM VU0409551, or co-application of VU0409551 and
DHPG, respectively. Traces in right panels in (G) and (H) are scaled to the peak of AMPAR-EPSCs and superimposed, demonstrating that VU0409551 did not
potentiate the EPSCNMDA/EPSCAMPA ratio when applied alone or co-applied with DHPG. (I and J) Summary of the effects of 3 mM DHPG, 10 mM VU0409551,
and 10 mMVU0409551 along with 3 mMDHPG on EPSCAMPA amplitude and the EPSCNMDA/EPSCAMPA ratio, respectively (n = 4–6). Data represent mean ± SEM,
*p < 0.05, **p < 0.005.asleep, leading to significant reduction in non-rapid eye move-
ment (NREM) and REM sleep (Figure 5). A 10 mg/kg dose had
a modest effect on vigilance states, decreasing time asleep for
2 hr post-administration. A dose of 60 mg/kg VU0409551 signif-
icantly decreased the total time spent in NREM and REM sleep
for up to 7 hr post-administration (Figure 5).
Antipsychotic-like and Procognitive Efficacy of
VU0409551
Discovery and optimization of VU0409551 as anmGlu5 PAM that
has an excellent PK profile and does not potentiate coupling of
mGlu5 to NMDAR currents provides an unprecedented opportu-nity to directly assess the importance of potentiation of NMDAR
signaling in antipsychotic-like and cognition-enhancing effects
of mGlu5 PAMs in rodent models. Two primary models used
to assess antipsychotic-like activity of mGlu5 PAMs include
reversal of NMDAR antagonist- or amphetamine-induced hyper-
locomotion (AHL) and reversal of pharmacologically induced dis-
ruptions in prepulse inhibition (PPI) of the acoustic startle reflex.
Interestingly, pretreatment (30 min) of rats with VU0409551 (10–
100 mg/kg) reversed the increased locomotor activity induced
by the NMDAR antagonist MK-801 (0.2 mg/kg, subcutane-
ous [s.c.], Figure 6A). The minimal effective dose (MED) of
VU0409551 was 10 mg/kg with a maximum reversal of 49.7%Neuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc. 1033
Figure 4. In Contrast to Other mGlu5 PAMs, VU0409551 Does Not Potentiate NMDAR-Mediated Hippocampal Synaptic Plasticity
(A) VU0409551 does not potentiate NMDAR-mediated, theta burst stimulation-induced long-term potentiation (LTP). Saturation TBS resulted in a significant
increase in fEPSP slope 35min after stimulation. Threshold TBS resulted in a small increase in fEPSP slopemeasured 35min after stimulation. Bath application of
10 mM VU0409551 for 20 min, followed by threshold TBS, resulted in no change in fEPSP slope from threshold TBS alone. In contrast, bath application of 1 mM
VU0092273 for 20 min, followed by threshold TBS, resulted in a significant enhancement of fEPSP slope measured 35 min after stimulation. Inset shows
representative fEPSP traces for each condition for baseline (black trace) and 35 min after TBS (gray trace).
(B) Quantification of the change in fEPSP slope measured 35 min after TBS stimulation. In contrast to VU0092273, bath application of VU0409551 for 20 min
followed by threshold TBS did not result in significant LTP 35min after stimulation (p = 0.0002, n = 6–11). Data represent mean ± SEM. **p < 0.01, when compared
with threshold TBS.at the highest dose (Figure 6A). In addition, pretreatment (30min)
with VU0409551 (3–100 mg/kg) dose-dependent reversed
increased locomotor activity induced by administration of
amphetamine (1 mg/kg, s.c.) with an MED of 3 mg/kg, an ED50
of 5.9 mg/kg, and a maximum reversal of 78.1% (Figures S6A
and S6B). VU0409551 terminal (1.5 hr) unbound brain concentra-
tion data from rat AHL studies were used to determine an in vivo
EC50 using individual animal concentration-efficacy data from all
dose groups. This analysis provided an EC50 of 97 nM with an
Emax of 82% for reversal of AHL. Additionally, reversal of AHL
by VU0409551 was blocked by the mGlu5 antagonist, MTEP,
supporting mGlu5-mediated antipsychotic-like efficacy (data
not shown). Finally, pretreatment (30 min) with VU0409551
(56.6 and 100 mg/kg) reversed amphetamine-induced disrup-
tions in PPI in rats (Figure S6C).
In addition to its antipsychotic-like activity, VU0409551demon-
strated robust cognition enhancement. VU0409551 induced a
dose-dependent enhancement of contextual fear conditioning
acquisition in rats. Pretreatment (30 min) with VU0409551 (0.3–
10mg/kg) prior to conditioning significantly enhanced acquisition
of fearmemoryassessed24hr later (Figure6B), demonstratingef-
ficacy of this novel mGlu5 PAM in enhancing an established form
of hippocampal-dependent cognitive function. Moreover, admin-
istration of VU0409551 (1–10 mg/kg) 30 min prior to exposure to
two identical objects resulted in a dose-dependent increase in
recognition memory in the novel object recognition task, another1034 Neuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc.commonly used rodent learning and memory paradigm depen-
dent upon hippocampal function (Figure 6C). To evaluate the ef-
fects of VU0409551 on working memory and executive function,
we used the operant delayed non-matching to position (DNMTP)
task. Pretreatment (60 min) with VU0409551 (10–60 mg/kg) prior
to the testing session increased the proportion of correct re-
sponses at a 10 and 20 s delay (60 mg/kg; Figure 6D) with no
change in total number of trials initiated (Figure S6D). Based on
the PK analysis, the doses of VU0409551 required to elicit anti-
psychotic-like and cognition-enhancing effects provide brain
concentrations that fit well with those required to potentiate
mGlu5-mediated responses in cell lines and in brain slices
(100 nM–30 mM). These data demonstrate that VU0409551 has
robust efficacy in rodent models used to predict antipsychotic-
like and cognition-enhancing effects that are similar to that
described for previousmGlu5 PAMs that potentiatemGlu5modu-
lation of NMDAR currents.
Repeated Administration of VU0409551 Does Not
Induce Detectable Changes in Fluoro-Jade C Staining
Previous studies reveal that some mGlu5 PAMs can induce se-
vere epileptiform activity, behavioral convulsions (Parmentier-
Batteur et al., 2014; Rook et al., 2013), and neuronal death
(Parmentier-Batteur et al., 2014) in rodents as assessed by
measuring increases in staining for Fluoro-Jade C (FJC), which
selectively stains degenerating neurons (Schmued et al., 1997).
Figure 5. VU0409551 Displays Wake-Pro-
moting Effects In Vivo
Sleep-wake electroencephalography (EEG) studies
demonstrate that VU0409551 (10 or 60 mg/kg),
administered at the second hr of the light cycle,
dose-dependently decreases the percent time
spent asleep (p < 0.0001, n = 8). Sleep polygraphic
variables weremeasured in rats for 24 hr beginning
at the start of the light cycle. Data representmean±
SEM. *p < 0.05.Similar to previous reports with 5PAM523 (Parmentier-Batteur
et al., 2014), we found that VU0424465 induced cell death, as as-
sessed by the number of FJC-positive neurons in the auditory
cortex and adjacent cortical regions 24 hr following a single rela-
tively low dose (3mg/kg, intraperitoneal [i.p], Figures 7A and 7B).
In contrast, daily administration of a high dose of VU0409551
(120 mg/kg, p.o.) for 4 consecutive days did not induce in FJC
staining in sections harvested from rats 24 hr following the last
dose (Figures 7A and 7B).
In order to determine the PK of VU0409551 following repeat
(once daily for 4 days) administration (120 mg/kg, p.o., 75% PEG
400 in water) used in FJC studies, a satellite PK study was per-
formed using an identical design; plasmaconcentrationswere ob-
tained at 3, 7, and 24 hr post-administration on day 1 and day 4
(FigureS7). In this study,VU0409551displayedsimilar, highCmax,p
and exposure on day 1 (Cmax,p, 7.0 mM; AUC0-last, 96 mM*hr) and
day 4 (Cmax,p, 7.5 mM; AUC0-last, 95 mM*hr). Thus, the exposure
was maintained at levels far in excess of those required to
achieve maximal efficacy over this 4-day dosing period.
Finally, consistent with previous reports (Parmentier-Batteur
et al., 2014; Rook et al., 2013), VU0424465 and 5PAM523
induced behavioral convulsions in rats that could be assessed
using the Racine scale of behavioral convulsions (Figure 7C). In
contrast VU0409551, at doses up to 100 times that required
for measureable efficacy in behavioral models (120 mg/kg), did
not induce behavioral convulsions in rats (Figure 7C). In addition,
while chronic administration of previous mGlu5 PAMs, such as
5PAM523, led to progressive worsening of seizure activity (Par-
mentier-Batteur et al., 2014), VU0409551 did not induce behav-
ioral convulsions after repeated once-daily administration of high
doses (450 mg/kg) over 14 days (data not shown). Thus,
VU0409551 does not have detectable toxic effects at the doses
well above those used for these behavioral studies.
DISCUSSION
Converging evidence suggests that NMDAR hypofunction is a
primary risk factor for schizophrenia (Coyle et al., 2012; Field
et al., 2011; Matosin and Newell, 2013; Timms et al., 2013).
NMDAR and mGlu5 are co-localized at postsynaptic sites impli-
cated in the pathology of schizophrenia and their intracellular
domains are physically connected via scaffold proteins (GaoNeuron 86, 1029–10et al., 2013; Hu et al., 2012; Matosin and
Newell, 2013; Park et al., 2013; Shepherd
and Huganir, 2007), facilitating the poten-
tiation ofNMDARactivity bymGlu5 activa-tion (Ayala et al., 2009; Homayoun et al., 2004; Mannaioni et al.,
2001; Marino and Conn, 2002). Numerous reports demonstrate
that selectivemGlu5 PAMshave efficacy in animalmodels of psy-
chosis andcognition (Darrah et al., 2008;Gastambide et al., 2013;
Gregory et al., 2013a; Kinney et al., 2003; Liu et al., 2008; Noetzel
et al., 2012; Rodriguez et al., 2010), and these effects have been
hypothesized to result from direct potentiation of NMDAR cur-
rents. In support of this hypothesis, previous studies revealed
that mGlu5 PAMs potentiate mGlu5 modulation of NMDAR
currents in pyramidal cells of the hippocampus (O’Brien et al.,
2004), andwenowconfirm thesepreviousfindingsusingmultiple,
structurally unrelated mGlu5 PAMs. However, potentiation of
mGlu5 coupling toGaq in postsynaptic neurons also facilitates ac-
tivity in these forebrain circuits through effector systems indepen-
dent of NMDAR activation. Discovery of VU0409551 as a potent
mGlu5 PAM that displays signaling bias and does not potentiate
mGlu5 coupling toNMDARcurrentswhile exhibiting robust in vivo
efficacy in rodent models provides an exciting advance in our
understanding of mGlu5 pharmacology and suggests that mGlu5
acts in concert with NMDARs to modulate brain circuits that are
impacted in these models rather than exerting actions that are
fully dependent on mGlu5 modulation of NMDAR signaling.
While these data are consistent with a clear stimulus bias and
lack of effect of VU0409551 on mGlu5 modulation of NMDAR
currents, it is important to note that VU0409551 could cause
an indirect potentiation of NMDAR function in some neuronal
populations by depolarizing neurons, reducing the voltage-
dependent Mg2+ block of NMDAR channels and thereby in-
crease NMDAR currents indirectly. However, DHPG-induced
depolarization of pyramidal cells in hippocampal area CA1 in
rats is mediated by mGlu1 rather than mGlu5 (Mannaioni et al.,
2001). Thus, selective potentiation of mGlu5 is not likely to poten-
tiate NMDAR function by depolarizing the pyramidal cells at this
particular synapse. However, mGlu5 activation inhibits the slow
AHP current (IAHP) and thereby increases excitability in CA1 py-
ramidal cells (Mannaioni et al., 2001). Thus, the overall physio-
logical effects of mGlu5 activation in forebrain circuits include
multiple actions that are independent of direct modulation of
NMDAR currents but act in concert with NMDAR signaling to
enhance transmission through circuits that are impacted in
schizophrenia and relevant animal models. This and other mech-
anisms by which mGlu5 activation can enhance transmission at40, May 20, 2015 ª2015 Elsevier Inc. 1035
Figure 6. VU0409551 Demonstrates Antipsychotic-like Activity and Cognition Enhancement in Rodent Behavioral Models
(A) VU0409551 (10–100mg/kg) reversesMK-801-induced hyperlocomotion in rats with aminimum effective dose of 10mg/kg andmaximum reversal of 49.7% at
100mg/kg. Data are expressed as themean total number of beam breaks per 5 min intervals ± SEM. Area under the curve from time interval t = 60 to 120min was
quantified for each treatment group and expressed as total ambulations. Percent reversal was calculated after normalizing to the vehicle + MK-801 treatment
group (p < 0.0001, n = 10–12).
(B) VU0409551 dose-dependently enhances acquisition of contextual fear conditioning in rats. Pretreatment with 1, 3, 5.6, and 10 mg/kg VU0409551 prior to
conditioning significantly enhanced acquisition of fear conditioning assessed 24 hr later (p = 0.0005, n = 10–13). Data are expressed asmean ± SEM. ***p < 0.001,
**p < 0.01, and *p < 0.05.
(C) VU0409551 dose-dependently enhances recognition memory in rats. Pretreatment with 3 and 10 mg/kg VU0409551 prior to exposure to identical objects
significantly enhanced recognition memory assessed 24 hr later (p = 0.0014, n = 19). Data are expressed as mean ± SEM. ***p < 0.001 and *p < 0.05.
(D) VU0409551 demonstrates pro-cognitive effects in the delayed non-matching to position task in rats. Pretreatment with VU0409551 (10–60 mg/kg) prior to
testing significantly increased the proportion of correct responses at 10 s and 20 s delays, respectively (p = 0.0236, n = 15–35). Data are expressed as mean ±
SEM. *p < 0.05.synapses where NMDARs play important roles would likely
enhance transmission through these circuits and may be
involved in the efficacy of mGlu5 PAMs.
Similar to previously reported mGlu5 PAMs, VU0409551 ex-
hibits selective, potent potentiation of mGlu5-mediated calcium
mobilization. Importantly, VU0409551 does not possess intrinsic
allosteric agonist activity in induction of calcium mobilization in
cell-based assays or native systems but potentiates glutamate-
induced increases in intracellular calcium, therefore displaying
pure PAM activity at mGlu5 in this assay. Previous studies sug-
gest that allosteric agonist or ‘‘ago-PAM’’ activity in inducing cal-
cium mobilization is a primary factor that can contribute to
adverse effects of mGlu5 PAMs (Conn et al., 2014; Rook et al.,
2013). Thus, the lack of ago-PAM activity in VU0409551 in this
assay is a critical property for avoiding adverse effects. However,
mGlu5 PAMs that lack allosteric agonist activity can still lead to
seizures and cell death after chronic administration of high doses
(Parmentier-Batteur et al., 2014). This, coupled with the estab-
lished role of NMDAR activation in excitotoxicity throughout the
CNS (Stone and Burton, 1988), raises the possibility that agents1036 Neuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc.that do not potentiate mGlu5 modulation of NMDAR currents
could provide the desired efficacy while reducing the risk
of neurotoxic effects. Thus, the stimulus bias provided by
VU0409551 that allows potentiation of mGlu5 signaling through
Gaq without potentiation of mGlu5 coupling to NMDAR current
modulation could be a significant factor that leads to the
improved safety profile that we observe for this novel mGlu5
PAM, in which no toxicity is observed in the dose range that pro-
vides preclinical efficacy in rats. However, it is important to note
that there can be species differences in the PAM-induced activa-
tion of specific signaling cascades (Conn et al., 2014; Croy et al.,
2014) or pharmacokinetic differences across species, all ofwhich
may affect their net in vivo effects. Thus, this type of stimulus bias
can be species dependent and we cannot extrapolate beyond
the current studies to make predictions regarding effects of
VU0409551 on NMDAR currents and likely safety of this com-
pound in other species. Indeed, when administered chronically
at very high doses (360 mg/kg, once daily for 1 month), we
have found evidence that VU0409551 can induce FJC staining
(P.J.C., unpublished data).
Figure 7. Repeat Administration of
VU0409551 Does Not Result in Positive
Fluoro-Jade C Staining in the Rat Brain
(A and B) mGlu5 ago-PAM VU0424465 (3 mg/kg)
induces positive Fluoro-Jade C (FJC) staining in
the auditory cortex 24 hr after acute dosing.
Unlike VU0424465, VU0409551 does not induce
neurotoxicity in rats at doses above those
required for robust in vivo efficacy in behavioral
assays as demonstrated by negative FJC staining
following repeat dosing of 120 mg/kg once daily
for 4 consecutive days (p < 0.0001, n = 3). Data
represent mean ± SEM. ***p < 0.0001, when
compared with VU0409551.
(C) mGlu5 PAMs VU0424465 (3 mg/kg) and PAM
5PAM523 (56.6 mg/kg) induce robust behavioral
convulsions as measured by the modified Racine
scale (0–5). VU0409551 is void of seizure activity
following acute or repeat dosing (120 mg/kg)
once daily for 4 consecutive days. Data represent
mean ± SEM.It was especially interesting to find that VU0409551 does not
potentiate TBS-induced LTP in the hippocampus. This is in
contrast to previous mGlu5 PAMs, which induce robust potenti-
ation of TBS-LTP (Ayala et al., 2009; Noetzel et al., 2013).
Induction of LTP at this synapse is known to be NMDAR depen-
dent (Ben-Ari et al., 1992; Harris et al., 1984; Mu¨ller et al., 2013).
Thus, this finding, together with the lack of ability of VU0409551
to potentiate mGlu5 modulation of NMDAR currents, is consis-
tent with the hypothesis that mGlu5-induced potentiation of hip-
pocampal LTP is dependent on the ability of mGlu5 to potentiate
NMDAR currents (Ben-Ari et al., 1992; Collingridge et al., 2013;
Mannaioni et al., 2001). Interestingly, VU0409551 did enhance
fear conditioning and novel object recognition, which are estab-
lished models of hippocampal-dependent cognitive function
(Franc¸a et al., 2014; Maren and Holt, 2000). VU0409551 also
improved performance in an operant DNMTP task, which as-
sesses cortical-dependent workingmemory and executive func-
tion. These data suggest that the cognition-enhancing effects of
mGlu5 PAMs in are not dependent upon potentiation of NMDAR
currents or LTP. However, as mentioned above, mGlu5 activa-
tion has a broad range of effects in the hippocampus and cortical
circuits that are unrelated to modulation of NMDAR currents but
increase overall transmission through the hippocampal circuit. In
the future, it will be important to perform further studies to better
understand the mechanisms by which mGlu5 PAMs enhance
cognitive function.EXPERIMENTAL PROCEDURES
In Vitro Assays
Cell Culture and In Vitro Assays
HEK293A cells stably expressing rat mGlu5 or mGlu1 and primary rat cortical
astrocytes (Lonza) were maintained and measurement of mGlu5- or mGlu1-
mediated intracellular Ca2+ mobilization was performed as previouslyNeuron 86, 1029–10described (Hammond et al., 2010; Rodriguez
et al., 2010; Rook et al., 2013). For selectivity
screening, calcium flux in HEK293 cells stably ex-pressing rat mGlu1 or thallium flux through GIRK channels in HEK293-GIRK
cells expressing mGlu subtype 2, 3, 4, 6, 7, or 8 was measured as described
in Supplemental Experimental Procedures (Hammond et al., 2010; Niswender
et al., 2008; Rodriguez et al., 2010). Measurement of mGlu5-mediated ERK
phosphorylation was performed in HEK293A cells stably expressing rat
mGlu5 using the ALPHAScreen-based ERK Surefire kit (Perkin-Elmer, TGR
Biosciences) as described in Supplemental Experimental Procedures and pre-
viously (Gregory et al., 2012).
In Vivo Studies
Animals
All present studies used male Sprague Dawley (SD) rats (Harlan) with the
exception of the delayed non-matching to position task (male Lister-hooded
rats [Harlan]), which were cared for in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals. All experimental
procedures were approved by the Vanderbilt University Animal Care and Use
Committee. Unless otherwise stated, all VU0409551 dosing was performed
orally in 20% b-cyclodextrin at 3 ml/kg. Additional detailed methods for animal
studies below can be found in the Supplemental Experimental Procedures.
Brain Slice Electrophysiology
Whole-Cell Voltage- and Current-Clamp Recordings
Transverse hippocampal slices were prepared from rats (age 17–28 days)
(Charles River). Whole-cell recordings were made from hippocampal CA1 py-
ramidal neuron soma. NMDA receptor-mediated responses were induced by
pressure ejection of 0.5–1 mM NMDA to the dendritic field near the soma of
the recorded cell every 30 s through a patch pipette using a Picospritzer II
(General Valve). This experiment was carried out in the presence of tetrodo-
toxin (1 mM), and the cell was voltage clamped at 65 to 70 mV or recorded
at restingmembrane potential under current clamp. For the studies of synaptic
NMDAR currents, EPSCsAMPA and EPSCsNMDA were evoked by electrical
stimulation of Schaffer collaterals every 30 s and recorded at holding potential
of 60 mV and +40 mV, respectively, in the presence of 20 mM bicuculline. All
drugs were bath applied. Data were analyzed using Clampfit 10.2, Origin 6
(OriginLab) and Prism 5.0 (GraphPad Software).
Extracellular Field Potential Recordings
Transverse hippocampal slices were prepared from young adult (age 29–
36 days) rats (Charles River) (Ayala et al., 2009; Noetzel et al., 2012). A bipo-
lar-stimulating electrode was utilized to stimulate the Schaffer collaterals40, May 20, 2015 ª2015 Elsevier Inc. 1037
and field potential recordings were acquired from the CA1. mGlu5 compounds
were applied to the bath for 10–20 min and chemically induced mGlu LTD was
initiated by the application of DHPG for 10 min. Threshold LTP was induced by
one train of theta burst stimulation (TBS; nine bursts of four pluses at 100 Hz,
230-ms interburst interval). Saturated LTP was induced by four trains of 10 Hz
TBS (nine bursts of four pulses at 100 Hz, 100-ms interburst interval). Data
were analyzed using Clampfit 10.2 and GraphPad Prism 5.0 (Noetzel et al.,
2012).
Drug Metabolism and Pharmacokinetics in Rat
The in vitro and in vivo rat drug metabolism and pharmacokinetic properties of
VU0409551 were determined essentially as previously described (Bridges
et al., 2013; Gregory et al., 2013a; Jones et al., 2012).
Rat Chronic Dosing Satellite PK for Fluoro-Jade Studies
In order to determine the PK of VU0409551 following chronic administration
(once daily [QD] for 4 days; 120 mg/kg, p.o., vehicle: 70% PEG 400 in water)
to non-fasted rats used in Fluoro-Jade studies, we obtained serial blood sam-
ples and plasma concentrations determined at 3, 7, and 24 hr post-administra-
tion on day 1 and day 4. Samples and data were analyzed as described above
via LC-MS/MS quantification.
Behavioral Studies
Sleep-Wake Electroencephalography Studies
Electroencephalography (EEG) and electromyography (EMG) data were re-
corded from rats (250–275 g) beginning at the start of the light cycle.
VU0409551 was then administered (vehicle, 10, or 60 mg/kg) at the second
hour of the light period. Sleep polygraphic variables were measured for a
period of 22 hr after compound administration in rats. EEG and EMGwaveform
data were collected using Dataquest A.R.T. 4.3 software (DSI) using a contin-
uous sampling method. Telemetric data were sampled at a rate of 500 Hz and
transmitted via a receiver (RPC-2, DSI, MN) placed below the cage of each rat.
Data were scored manually by a blinded observer into 10 s epoch using
Neuroscore 3.0 software (Data Sciences International) to determine changes
in sleep-wake stages following dosing based upon accepted characteristic
oscillatory patterns. Sleep-wake stages were scored in 10 s epochs then
NREM and REM sleep time was combined into 60 min bins to examine the
percent of time spent in total sleep across the first 22 hr cycle following
compound administration.
MK-801-Induced Hyperlocomotion
Effects of VU0409551 on MK-801-induced hyperlocomotion in rats
were determined (Rodriguez et al., 2010) using an open-field chamber (Kinder-
Scientific). At t = 30, rats were administered vehicle or VU0409551 (10–100mg/
kg) followed by MK-801 (0.2 mg/kg, s.c., saline, 1 ml/kg) at t = 60 min. Loco-
motor activity was measured for an additional 60 min. Changes in locomotor
activity were measured as the total number of photobeam breaks per 5 min
bins.
Contextual Fear Conditioning
Effects of VU0409551 on acquisition of contextual fear conditioning were eval-
uated in rats (275–300 g) (Lebois et al., 2010). Rats were given a 30 min pre-
treatment of VU0409551 (0.3–10 mg/kg) and placed in a sound-attenuating
conditioning chamber (Med Associates) in the presence of 1 ml of a 10% va-
nilla extract solution. Following a 2 min habituation period, rats received a
one shock-context pairing trials (1 s, 0.5 mA) and after 45 s were returned to
their home cages. Twenty-four hours later, the fear response was assessed
in the same conditioning environment for 2 min 45 s, measuring freezing
behavior in the absence of any shock stimuli or drug. Testing sessions were
recorded and time spent freezing was scored by blinded personnel (MED-
VFC-RS, MedAssociates).
Novel Object Recognition
Effects of VU0409551 on recognition memory were evaluated in rats (275–
300 g). Rats were habituated in an empty novel object recognition (NOR) arena
for 10min for 2 consecutive days.Onday 3, ratswere administered vehicle, 1, 3,
or 10 mg/kg of VU0409551 30 min before being placed into the NOR arena
containing two identical objects. Following a 10 min exposure period, rats
were placed back into their home cages, and 24 hr later returned to the arena
in which one of the previously exposed (familiar) objects was replaced by a
novel object. The rats were video recorded for 10 min while they explored the
objects. Time spent exploring each object was scored by a blinded observer.1038 Neuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc.Delayed Non-Matching to Position
Effects of VU0409551 on working memory and executive function were eval-
uated in the delayed non-matching to position (DNMTP) task using male
Lister-hooded rats (350–450 g). Rats were trained to ensure a high level of sta-
ble and accurate performance was obtained. Rats were administered vehicle
or VU0409551 (10–60 mg/kg) 60 min prior to testing. Four delay lengths (1, 10,
20, and 30 s) were used in this study with 15 trials occurring at each delay (60
trials total). Rats were allowed a maximum of 45 min to complete these trials.
Fluoro-Jade C Staining
Twenty-four hours after the last dose of VU0409551 or VU0424465, Fluoro-
jade C staining was performed on rat brains. Fluoro-jade C-positive neurons
within the auditory cortex were counted under 203 magnification. A total of
five sections per animal was quantified and the data are presented as mean
number of cells per section.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2015.03.063.
AUTHOR CONTRIBUTIONS
J.M.R. and Z.X. designed and performed experiments, analyzed data, and
wrote the manuscript. X.L., A.G., J.W.D., T.M.B., K.A.J., D.J.F., K.J.G.,
P.N.V., A.D.T., N.B., R.L.C., M.B., and M.T.N. performed experiments and
analyzed data; R.W.G., S.R.S., J.S.D., C.M.N., H.L., C.M., S.C.-C., J.A.,
J.M.B.-N., G.J.M., J.C.T., T.S., C.K.J., and C.W.L. supervised studies;
P.J.C. designed experiments, supervised studies, and wrote the manuscript.
ACKNOWLEDGMENTS
This work is supported by the National Institutes of Health (R01 MH062646,
R01 MH074953 R01 NS031373 (P.J.C.); U54 MH084659 (C.W.L.); and by
Janssen Research and Development. The authors would like to thank Dina
McGinnis, Kiran Gogi, Rocco D. Gogliotti, Mark Turlington, and Tom Van De
Casteele for their technical expertise. Fluoro-Jade C data analysis and presen-
tation were performed in part through the use of the Vanderbilt University Med-
ical Center Cell Imaging Shared Resource. P.N.V., S.R.S., C.M.N., J.S.D.,
C.K.J., C.W.L., and P.J.C. have received compensation from Johnson and
Johnson and are inventors on patents that protect multiple classes of mGlu5
PAMs. H.L., C.M., S.C.-C., J.A., J.M.B.-N., G.J.M., J.C.T., and T.S. are em-
ployees and shareholders of Janssen Research and Development.
Received: August 27, 2014
Revised: February 22, 2015
Accepted: March 24, 2015
Published: April 30, 2015
REFERENCES
Awad, H., Hubert, G.W., Smith, Y., Levey, A.I., and Conn, P.J. (2000).
Activation of metabotropic glutamate receptor 5 has direct excitatory effects
and potentiates NMDA receptor currents in neurons of the subthalamic nu-
cleus. J. Neurosci. 20, 7871–7879.
Ayala, J.E., Chen, Y., Banko, J.L., Sheffler, D.J., Williams, R., Telk, A.N.,
Watson, N.L., Xiang, Z., Zhang, Y., Jones, P.J., et al. (2009). mGluR5 positive
allosteric modulators facilitate both hippocampal LTP and LTD and enhance
spatial learning. Neuropsychopharmacology 34, 2057–2071.
Ben-Ari, Y., Aniksztejn, L., and Bregestovski, P. (1992). Protein kinase C mod-
ulation of NMDA currents: an important link for LTP induction. Trends
Neurosci. 15, 333–339.
Bridges, T.M., Rook, J.M., Noetzel, M.J., Morrison, R.D., Zhou, Y., Gogliotti,
R.D., Vinson, P.N., Xiang, Z., Jones, C.K., Niswender, C.M., et al. (2013).
Biotransformation of a novel positive allosteric modulator of metabotropic
glutamate receptor subtype 5 contributes to seizure-like adverse events in rats
involving a receptor agonism-dependentmechanism. DrugMetab. Dispos. 41,
1703–1714.
Brody, S.A., Conquet, F., and Geyer, M.A. (2004). Effect of antipsychotic treat-
ment on the prepulse inhibition deficit of mGluR5 knockout mice.
Psychopharmacology (Berl.) 172, 187–195.
Campbell, U.C., Lalwani, K., Hernandez, L., Kinney, G.G., Conn, P.J., and
Bristow, L.J. (2004). The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-
pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats.
Psychopharmacology (Berl.) 175, 310–318.
Collingridge, G.L., Kehl, S.J., andMcLennan, H. (1983). Excitatory amino acids
in synaptic transmission in the Schaffer collateral-commissural pathway of the
rat hippocampus. J. Physiol. 334, 33–46.
Collingridge, G.L., Volianskis, A., Bannister, N., France, G., Hanna, L., Mercier,
M., Tidball, P., Fang, G., Irvine, M.W., Costa, B.M., et al. (2013). The NMDA re-
ceptor as a target for cognitive enhancement. Neuropharmacology 64, 13–26.
Conn, P.J., Lindsley, C.W., Meiler, J., and Niswender, C.M. (2014).
Opportunities and challenges in the discovery of allosteric modulators of
GPCRs for treating CNS disorders. Nat. Rev. Drug Discov. 13, 692–708.
Coyle, J.T., Basu, A., Benneyworth, M., Balu, D., and Konopaske, G. (2012).
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implica-
tions. Handbook Exp. Pharmacol. 213, 267–295.
Croy, C.H., Schober, D.A., Xiao, H., Quets, A., Christopoulos, A., and Felder,
C.C. (2014). Characterization of the novel positive allosteric modulator,
LY2119620, at the muscarinic M(2) and M(4) receptors. Mol. Pharmacol. 86,
106–115.
Darrah, J.M., Stefani, M.R., and Moghaddam, B. (2008). Interaction of
N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on
behavioral flexibility using a novel operant set-shift paradigm. Behav.
Pharmacol. 19, 225–234.
Doherty, A.J., Palmer, M.J., Henley, J.M., Collingridge, G.L., and Jane, D.E.
(1997). (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but
no mGlu1, receptors expressed in CHO cells and potentiates NMDA re-
sponses in the hippocampus. Neuropharmacology 36, 265–267.
Field, J.R., Walker, A.G., and Conn, P.J. (2011). Targeting glutamate synapses
in schizophrenia. Trends Mol. Med. 17, 689–698.
Fitzjohn, S.M., Irving, A.J., Palmer, M.J., Harvey, J., Lodge, D., and
Collingridge, G.L. (1996). Activation of group I mGluRs potentiates NMDA
responses in rat hippocampal slices. Neurosci. Lett. 203, 211–213.
Franc¸a, A.S., do Nascimento, G.C., Lopes-dos-Santos, V., Muratori, L.,
Ribeiro, S., Loba˜o-Soares, B., and Tort, A.B. (2014). Beta2 oscillations (23-
30 Hz) in the mouse hippocampus during novel object recognition. Eur. J.
Neurosci. 40, 3693–3703.
Gao, C., Tronson, N.C., and Radulovic, J. (2013). Modulation of behavior
by scaffolding proteins of the post-synaptic density. Neurobiol. Learn. Mem.
105, 3–12.
Gastambide, F., Gilmour, G., Robbins, T.W., and Tricklebank, M.D. (2013). The
mGlu5 positive allosteric modulator LSN2463359 differentially modulates
motor, instrumental and cognitive effects of NMDA receptor antagonists in
the rat. Neuropharmacology 64, 240–247.
Gilmour, G., Broad, L.M., Wafford, K.A., Britton, T., Colvin, E.M., Fivush, A.,
Gastambide, F., Getman, B., Heinz, B.A., McCarthy, A.P., et al. (2013).
In vitro characterisation of the novel positive allosteric modulators of the
mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep
architecture and operant responding in the rat. Neuropharmacology 64,
224–239.
Gregory, K.J., Noetzel, M.J., Rook, J.M., Vinson, P.N., Stauffer, S.R.,
Rodriguez, A.L., Emmitte, K.A., Zhou, Y., Chun, A.C., Felts, A.S., et al.
(2012). Investigating metabotropic glutamate receptor 5 allosteric modulator
cooperativity, affinity, and agonism: enriching structure-function studies and
structure-activity relationships. Mol. Pharmacol. 82, 860–875.
Gregory, K.J., Herman, E.J., Ramsey, A.J., Hammond, A.S., Byun, N.E.,
Stauffer, S.R., Manka, J.T., Jadhav, S., Bridges, T.M., Weaver, C.D., et al.(2013a). N-aryl piperazine metabotropic glutamate receptor 5 positive allo-
steric modulators possess efficacy in preclinical models of NMDA hypofunc-
tion and cognitive enhancement. J. Pharmacol. Exp. Ther. 347, 438–457.
Gregory, K.J., Nguyen, E.D., Reiff, S.D., Squire, E.F., Stauffer, S.R., Lindsley,
C.W., Meiler, J., and Conn, P.J. (2013b). Probing the metabotropic glutamate
receptor 5 (mGlu5) positive allosteric modulator (PAM) binding pocket: discov-
ery of point mutations that engender a ‘‘molecular switch’’ in PAM pharma-
cology. Mol. Pharmacol. 83, 991–1006.
Hammond, A.S., Rodriguez, A.L., Townsend, S.D., Niswender, C.M., Gregory,
K.J., Lindsley, C.W., and Conn, P.J. (2010). Discovery of a Novel Chemical
Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology.
ACS Chem. Neurosci. 1, 702–716.
Harris, E.W., Ganong, A.H., and Cotman, C.W. (1984). Long-term potentiation
in the hippocampus involves activation of N-methyl-D-aspartate receptors.
Brain Res. 323, 132–137.
Henry, S.A., Lehmann-Masten, V., Gasparini, F., Geyer, M.A., and Markou, A.
(2002). The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist
LY314582, augments PCP effects on prepulse inhibition and locomotor activ-
ity. Neuropharmacology 43, 1199–1209.
Homayoun, H., Stefani, M.R., Adams, B.W., Tamagan, G.D., andMoghaddam,
B. (2004). Functional Interaction Between NMDA and mGlu5 Receptors:
Effects on Working Memory, Instrumental Learning, Motor Behaviors, and
Dopamine Release. Neuropsychopharmacology 29, 1259–1269.
Hu, J.H., Yang, L., Kammermeier, P.J., Moore, C.G., Brakeman, P.R., Tu, J.,
Yu, S., Petralia, R.S., Li, Z., Zhang, P.W., et al. (2012). Preso1 dynamically reg-
ulates group I metabotropic glutamate receptors. Nat. Neurosci. 15, 836–844.
Huber, K.M., Roder, J.C., and Bear, M.F. (2001). Chemical induction of
mGluR5- and protein synthesis—dependent long-term depression in hippo-
campal area CA1. J. Neurophysiol. 86, 321–325.
Jones, C.K., Bubser, M., Thompson, A.D., Dickerson, J.W., Turle-Lorenzo, N.,
Amalric, M., Blobaum, A.L., Bridges, T.M., Morrison, R.D., Jadhav, S., et al.
(2012). The metabotropic glutamate receptor 4-positive allosteric modulator
VU0364770 produces efficacy alone and in combination with L-DOPA or an
adenosine 2A antagonist in preclinical rodent models of Parkinson’s disease.
J. Pharmacol. Exp. Ther. 340, 404–421.
Kinney, G.G., Burno, M., Campbell, U.C., Hernandez, L.M., Rodriguez, D.,
Bristow, L.J., and Conn, P.J. (2003). Metabotropic glutamate subtype 5 recep-
tors modulate locomotor activity and sensorimotor gating in rodents.
J. Pharmacol. Exp. Ther. 306, 116–123.
Kinney, G.G., O’Brien, J.A., Lemaire, W., Burno, M., Bickel, D.J., Clements,
M.K., Chen, T.B., Wisnoski, D.D., Lindsley, C.W., Tiller, P.R., et al. (2005). A
novel selective positive allosteric modulator of metabotropic glutamate recep-
tor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral
models. J. Pharmacol. Exp. Ther. 313, 199–206.
Lebois, E.P., Bridges, T.M., Lewis, L.M., Dawson, E.S., Kane, A.S., Xiang, Z.,
Jadhav, S.B., Yin, H., Kennedy, J.P., Meiler, J., et al. (2010). Discovery and
characterization of novel subtype-selective allosteric agonists for the investi-
gation of M(1) receptor function in the central nervous system. ACS Chem.
Neurosci. 1, 104–121.
Liu, F., Grauer, S., Kelley, C., Navarra, R., Graf, R., Zhang, G., Atkinson, P.J.,
Popiolek, M., Wantuch, C., Khawaja, X., et al. (2008). ADX47273 [S-(4-fluoro-
phenyl)-3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl-metha-
none]: a novel metabotropic glutamate receptor 5-selective positive allosteric
modulator with preclinical antipsychotic-like and procognitive activities.
J. Pharmacol. Exp. Ther. 327, 827–839.
Mannaioni, G., Marino, M.J., Valenti, O., Traynelis, S.F., and Conn, P.J. (2001).
Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyrami-
dal cell function. J. Neurosci. 21, 5925–5934.
Maren, S., and Holt, W. (2000). The hippocampus and contextual memory
retrieval in Pavlovian conditioning. Behav. Brain Res. 110, 97–108.
Marino, M.J., and Conn, P.J. (2002). Direct and indirect modulation of the
N-methyl D-aspartate receptor. Curr. Drug Targets CNS Neurol. Disord. 1,
1–16.Neuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc. 1039
Matosin, N., and Newell, K.A. (2013). Metabotropic glutamate receptor 5 in
the pathology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 37,
256–268.
Mu¨ller, L., Tokay, T., Porath, K., Ko¨hling, R., and Kirschstein, T. (2013).
Enhanced NMDA receptor-dependent LTP in the epileptic CA1 area via upre-
gulation of NR2B. Neurobiol. Dis. 54, 183–193.
Niswender, C.M., and Conn, P.J. (2010). Metabotropic glutamate receptors:
physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50,
295–322.
Niswender, C.M., Johnson, K.A., Luo, Q., Ayala, J.E., Kim, C., Conn, P.J., and
Weaver, C.D. (2008). A novel assay of Gi/o-linked G protein-coupled receptor
coupling to potassium channels provides new insights into the pharmacology
of the group III metabotropic glutamate receptors. Mol. Pharmacol. 73, 1213–
1224.
Noetzel, M.J., Rook, J.M., Vinson, P.N., Cho, H.P., Days, E., Zhou, Y.,
Rodriguez, A.L., Lavreysen, H., Stauffer, S.R., Niswender, C.M., et al. (2012).
Functional impact of allosteric agonist activity of selective positive allosteric
modulators of metabotropic glutamate receptor subtype 5 in regulating central
nervous system function. Mol. Pharmacol. 81, 120–133.
Noetzel, M.J., Gregory, K.J., Vinson, P.N., Manka, J.T., Stauffer, S.R.,
Lindsley, C.W., Niswender, C.M., Xiang, Z., and Conn, P.J. (2013). A novel
metabotropic glutamate receptor 5 positive allosteric modulator acts at a
unique site and confers stimulus bias to mGlu5 signaling. Mol. Pharmacol.
83, 835–847.
O’Brien, J.A., Lemaire, W., Wittmann, M., Jacobson, M.A., Ha, S.N., Wisnoski,
D.D., Lindsley, C.W., Schaffhauser, H.J., Rowe, B., Sur, C., et al. (2004). A
novel selective allosteric modulator potentiates the activity of native metabo-
tropic glutamate receptor subtype 5 in rat forebrain. J. Pharmacol. Exp. Ther.
309, 568–577.
Park, J.M., Hu, J.H., Milshteyn, A., Zhang, P.W., Moore, C.G., Park, S., Datko,
M.C., Domingo, R.D., Reyes, C.M., Wang, X.J., et al. (2013). A prolyl-isom-
erase mediates dopamine-dependent plasticity and cocaine motor sensitiza-
tion. Cell 154, 637–650.
Parmentier-Batteur, S., O’Brien, J.A., Doran, S., Nguyen, S.J., Flick, R.B.,
Uslaner, J.M., Chen, H., Finger, E.N., Williams, T.M., Jacobson, M.A., and
Hutson, P.H. (2012). Differential effects of the mGluR5 positive allosteric
modulator CDPPB in the cortex and striatum following repeated administra-
tion. Neuropharmacology 62, 1453–1460.
Parmentier-Batteur, S., Hutson, P.H., Menzel, K., Uslaner, J.M., Mattson, B.A.,
O’Brien, J.A., Magliaro, B.C., Forest, T., Stump, C.A., Tynebor, R.M., et al.
(2014). Mechanism based neurotoxicity of mGlu5 positive allosteric modula-1040 Neuron 86, 1029–1040, May 20, 2015 ª2015 Elsevier Inc.tors—development challenges for a promising novel antipsychotic target.
Neuropharmacology 82, 161–173.
Peavy, R.D., Sorensen, S.D., and Conn, P.J. (2002). Differential regulation of
metabotropic glutamate receptor 5-mediated phosphoinositide hydrolysis
and extracellular signal-regulated kinase responses by protein kinase C in
cultured astrocytes. J. Neurochem. 83, 110–118.
Rammes, G., Palmer, M., Eder, M., Dodt, H.U., Zieglga¨nsberger, W., and
Collingridge, G.L. (2003). Activation of mGlu receptors induces LTD without
affecting postsynaptic sensitivity of CA1 neurons in rat hippocampal slices.
J. Physiol. 546, 455–460.
Rodriguez, A.L., Grier, M.D., Jones, C.K., Herman, E.J., Kane, A.S., Smith,
R.L., Williams, R., Zhou, Y., Marlo, J.E., Days, E.L., et al. (2010). Discovery
of novel allosteric modulators of metabotropic glutamate receptor subtype 5
reveals chemical and functional diversity and in vivo activity in rat behavioral
models of anxiolytic and antipsychotic activity. Mol. Pharmacol. 78, 1105–
1123.
Rook, J.M., Noetzel, M.J., Pouliot, W.A., Bridges, T.M., Vinson, P.N., Cho,
H.P., Zhou, Y., Gogliotti, R.D., Manka, J.T., Gregory, K.J., et al. (2013).
Unique signaling profiles of positive allosteric modulators of metabotropic
glutamate receptor subtype 5 determine differences in in vivo activity. Biol.
Psychiatry 73, 501–509.
Schmued, L.C., Albertson, C., and Slikker, W., Jr. (1997). Fluoro-Jade: a novel
fluorochrome for the sensitive and reliable histochemical localization of
neuronal degeneration. Brain Res. 751, 37–46.
Sheffler, D.J., and Conn, P.J. (2008). Allosteric potentiators of metabotropic
glutamate receptor subtype 1a differentially modulate independent signaling
pathways in baby hamster kidney cells. Neuropharmacology 55, 419–427.
Shepherd, J.D., and Huganir, R.L. (2007). The cell biology of synaptic plas-
ticity: AMPA receptor trafficking. Annu. Rev. Cell Dev. Biol. 23, 613–643.
Stone, T.W., and Burton, N.R. (1988). NMDA receptors and ligands in the
vertebrate CNS. Prog. Neurobiol. 30, 333–368.
Timms, A.E., Dorschner, M.O., Wechsler, J., Choi, K.Y., Kirkwood, R.,
Girirajan, S., Baker, C., Eichler, E.E., Korvatska, O., Roche, K.W., et al.
(2013). Support for the N-methyl-D-aspartate receptor hypofunction hypothe-
sis of schizophrenia from exome sequencing in multiplex families. JAMA
Psychiatry 70, 582–590.
Zhang, Y., Rodriguez, A.L., and Conn, P.J. (2005). Allosteric potentiators of
metabotropic glutamate receptor subtype 5 have differential effects on
different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther.
315, 1212–1219.
